Condition
Stage II Renal Cell Cancer AJCC v7
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 3 (2)
Trial Status
Completed1
Active Not Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03055013Phase 3Active Not Recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT00326898Phase 3Completed
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
NCT02595918Phase 1Terminated
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
Showing all 3 trials